ACAD Stock Chart & Stats
$453.75
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$340.00 - $550.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)27.00
Market Cap
$74.37B
Enterprise Value$3.04K
Total Cash (Recent Filing)$851.46M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)11.1
Beta0.06
Next Earnings
Aug 04, 2026EPS Estimate
1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding171,235,870
10 Day Avg. Volume54
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$567.79Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability And Gross MarginsAcadia has shifted from losses (2021–2023) to sustained profitability in 2024–TTM with exceptionally high gross margins. Durable gross margin strength supports product-level cash generation and pricing power, enabling reinvestment in commercialization and R&D without immediate financing pressure.
Conservative Balance Sheet & CashThe company maintains a conservatively positioned balance sheet with very low leverage and a cash balance of ~$851M. This liquidity and low debt provide long-term financial flexibility to fund commercial expansion, upcoming clinical readouts, and operating needs while reducing near-term dilution risk.
Pipeline Catalysts And Market OpportunityNear-term clinical readouts (remlifanserin Ph2; trofinetide Japan Ph3) and a stated ~$11B peak sales opportunity reflect meaningful structural upside. Successful results would expand addressable markets, diversify revenue beyond NUPLAZID and DAYBUE, and justify continued commercial investment over the next 2–6 months.
Bears Say
High Gross-to-Net ReductionsMaterial gross-to-net deductions materially reduce net realized revenue and compress margins despite strong list sales. These structural payer and rebate dynamics can persist through multiple quarters, reduce cash conversion, and make revenue guidance and margin forecasts more sensitive to reimbursement trends.
Rising SG&A And Operating Leverage RiskA sizable, persistent SG&A increase to fund a ~30% salesforce expansion elevates fixed costs and execution risk. If product uptake or gross-to-net pressures underperform expectations, higher operating spend could keep margins volatile and prolong the timeline to consistent operating leverage improvements.
Regulatory Uncertainty For Trofinetide (Europe)An ongoing regulatory reexamination in Europe creates a durable approval and timing risk for a key pipeline asset. Negative or delayed outcomes would reduce near-term revenue prospects outside the U.S., increase development and regulatory costs, and lower the probability of achieving projected peak sales from that program.
ACAD FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest stock price was $340.00 and its highest was $550.00 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $74.37B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on May 06, 2026. The company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.893 by -$0.543.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is 1.03.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.35 in its last earnings report, missing expectations of $0.893. Following the earnings report the stock price went up 0.262%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in MX:ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$567.79 (― Downside)
$567.79 (― Downside)
Blogger Sentiment
Bullish
MX:ACAD Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
ACAD Stock 12 Month Forecast
Average Price Target
$567.79